Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes

Aisha I. Kelly-Cobbs,1 Roshini Prakash,2,4 Weiguo Li,1 Bindu Pillai,2,4 Sherif Hafez,2 Maha Coucha,1 Maribeth H. Johnson,3 Safia N. Ogbi,1 Susan C. Fagan,2,4 and Adviye Ergul1,2,4

1Department of Physiology, Georgia Regents University Augusta, Augusta, Georgia; 2Program in Clinical and Experimental Therapeutics, Georgia Regents University Augusta, Augusta, Georgia; 3Department of Biostatistics, Georgia Regents University Augusta, Augusta, Georgia; and 4Charlie Norwood Veterans Administration Medical Center, Augusta, Georgia

Submitted 25 September 2012; accepted in final form 14 January 2013

Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Hafez S, Coucha M, Johnson MH, Ogbi SN, Fagan SC, Ergul A. Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol 2013;304:H806–H815. First published January 18, 2013; doi:10.1152/ajpheart.00720.2012.—Hemorrhagic transformation is an important complication of acute ischemic stroke, particularly in diabetic patients receiving thrombolytic treatment with tissue plasminogen activator, the only approved drug for the treatment of acute ischemic stroke. The objective of the present study was to determine the effects of acute manipulation of potential targets for vascular protection [i.e., NF-κB, peroxynitrite, and matrix metalloproteinases (MMPs)] on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of the peroxynitrite decomposition catalyst 5,10,15,20-tetakis(4-sulfonatophenyl)prophyrinato iron (III), the nonspecific NF-κB inhibitor curcumin, or the broad-spectrum MMP inhibitor minocycline at reperfusion. Poststroke infarct volume, edema, hemorrhage, neurological deficits, and MMP-9 activity were evaluated. All acute treatments reduced MMP-9 and hemorrhagic transformation in diabetic groups. In addition, acute curcumin and minocycline therapy reduced edema in these animals. Improved neurologic function was observed in varying degrees with treatment, as indicated by beam-walk performance, modified Bederson scores, and grip strength; however, infarct size was similar to untreated diabetic animals. In control animals, all treatments reduced MMP-9 activity, yet bleeding was not improved. Neuroprotection was only conferred by curcumin and minocycline. Uncovering the underlying mechanisms contributing to the success of acute therapy in diabetes will advance tailored stroke therapies.

minocycline; curcumin; 5,10,15,20-tetakis(4-sulfonatophenyl)prophyrinato iron (III); nuclear factor-κB; vascular protection

WITHIN THE NEXT DECADE, the number of individuals living with diabetes is expected to rise dramatically (8). By 2030, the estimated global prevalence of the disease will exceed 437 million (53), and the vascular damage sustained during the course of the disease will increase the likelihood that these affected individuals will develop micro- and macrovascular complications, including acute ischemic stroke (AIS) (41). Historically, individuals 65 yr and older are disproportionately affected, but for the first time ever, there is an alarming increase in the number of Americans who are diagnosed at a younger age and face a prolonged course of diabetes (46). This trend poses a serious problem because recent findings suggest that the risk of AIS increases 3% with each year of diabetes and triples after 10 yr (5). In addition, diabetes complicates ischemic injury, leading to increased morbidity and poor functional recovery (7), but how diabetes worsens ischemic stroke is not fully delineated. Understanding these subtleties is essential in identifying targets for neurovascular protection and for developing therapeutic strategies tailored to this burgeoning at-risk population.

In a series of studies, we showed that there is extensive cerebrovascular remodeling and dysfunctional neovascularization that is characterized by increased matrix metalloproteinase (MMP)-2 and -9 activity in a lean and mild model of type 2 diabetes (T2D) (18, 28). Preexisting diabetes in conjunction with ischemia-reperfusion injury causes a rapid loss of myogenic tone via increased oxidative stress (i.e., peroxynitrite) (35), augments hemorrhagic transformation (HT), and worsens functional outcome despite the relatively smaller infarct size (19). Based on these findings, we asked the following question: “Does acute peroxynitrite scavenging improve stroke outcomes?” Proinflammatory responses initiated during ischemia-reperfusion involve the activation of the nuclear transcription factor NF-κB, which is responsible for upregulating genes coding for cytokines and growth factors and can directly modulate MMP activity (25, 47). Accordingly, the present study investigated the effect of NF-κB inhibition on MMP activity and neurovascular injury and outcomes in diabetic stroke. Moreover, prevention of cerebrovascular remodeling by glycemic control with metformin or MMP inhibition with minocycline started at the onset of diabetes reduces HT and improves outcome (18). Given that MMPs, and especially MMP-9, are associated with the breakdown of the blood-brain barrier (BBB) (3, 24) and ensuing HT in experimental models of stroke that used normoglycemic animals (12, 55), in the present study, we hypothesized that pharmacological inhibition of MMP-9 at reperfusion either directly or indirectly by inhibition of NF-κB or peroxynitrite will prevent HT and improve functional outcomes in diabetes (Fig. 1).

METHODS

Animals. In previous studies, our group has shown that 3 h of middle cerebral artery (MCA) occlusion (MCAO) and 21 h of reperfusion coincided with the development of a smaller infarcts and greater vascular injury (i.e., edema and HT) in the T2D Goto-Kakizaki (GK) rat model compared with normoglycemic control rats (18, 19, 38). Therefore, we selected this nonobese model of diabetes to study the effects of acute NF-κB and MMP inhibition on edema, HT, and neurological outcomes after transient focal cerebral ischemia. This spontaneously diabetic rat strain was derived from the repeated in-breeding of glucose-intolerant Wistar rats (27). For this reason, we...
chose to use weight-matched Wistar rats as normoglycemic control animals in these experiments. Glucose intolerance can be observed in GK rats as early as 2 wk of age in these animals, and the onset of moderate hyperglycemia can be as early as 5–6 wk of age (26). During weeks 6–12, plasma insulin levels are elevated and then decrease to levels lower than those observed in Wistar rats (27, 28). In contrast to the severely hyperglycemic streptozotocin-induced rat model of diabetes, whose glucose levels are typically above 300 mg/dl (34, 42), GK rats are moderately hyperglycemic, with plasma glucose levels similar to what has been observed in stroke patients (7, 33, 35). The colonies were used for the experiments outlined in this study (in-house bred or purchased from the Tampa colony, Taconic, Hudson, NY) have been purchased from the Tampa colony, Taconic, Hudson, NY (34, 42), GK rats (n = 46) from Crumrine et al. (11). Visual inspection of bleeding was identified in slices B–E only. A blinded investigator scored macroscopic bleeding in each slice (where 0 = normal ischemic damage or hemorrhage, 1 = dispersed individual petechiae, 2 = confluent petechiae, 3 = small diffuse hemorrhage or hematoma, and 4 = large diffuse hemorrhage or hematoma), and the total score for each animal was reported. Microscopic bleeding was quantified using a colorimetric hemoglobin detection assay (QuantiChrom Hemoglobin Assay Kit, BioAssay Systems, Haywood, CA). First, TTC-stained brain samples were homogenized in a 10% glycerol-Tris-buffered saline solution containing Tween 20. Samples were prepared and read at 562 nm using a standard microplate reader, and the hemoglobin concentration was calculated according to the manufacturer’s instructions. The color intensity of the three drugs used in the study interfered with the results of the colorimetric assay; therefore, all values were normalized with respect to the concentrations detected in the brains of nonstressed animals receiving the corresponding treatment.

**Neurological assessment.** A battery of tests was performed to evaluate neurological function at baseline and 24 h after stroke (just before euthanization). These included the seven-point beam walk described by Feeney et al. (22) and measurement of grip strength using a digital grip strength meter (Columbus Instruments, Columbus, OH) (30). A modified binary Bederson scoring system was also used to detect pathological postural reflexes (i.e., no resistance to push, circling, forearm flexion, and hindlimb extension).

**MMP activity.** For each treatment group, cerebral macrovessels from the nonischemic and ischemic brain hemispheres were isolated, homogenized, and analyzed for MMP-2 and -9 activity using gelatin zymography, as we have previously described (18, 28). Recombinant MMP-2 and -9 proteins (Calbiochem) were run in parallel with all samples, and the band intensity on zymogram gels was normalized to that of the standard to prevent gel-to-gel variability. Gelatinolytic activity was assessed by densitometric analysis (Gel-Pro version 3.1, Media Cybernetics, Carlsbad, CA).

**Statistical analysis.** Data are expressed as means ± SE. Data were evaluated for normality, and the appropriate transformations were used when necessary. Due to skewed distributions and small sample sizes, a rank transformation was used before analysis for infarct size and HT. A log transformation was used to stabilize the variance as a function of the mean for MMP-9 activity. Grip strength deficit percent was calculated as grip strength at baseline minus grip strength post-MCAO divided by the baseline value. A 2 × 2 ANOVA was used to study the effect of disease (Wistar vs. GK) and treatment (untreated vs. FeTTPs or curcumin or minocycline) and their interaction on infarct size, edema, HT, neurological assessments, grip strength deficit percent, MMP-9 activity, and blood flow. A significant interaction indicates

---

**Fig. 1.** Schematic of experimental hypothesis. Excess peroxynitrite formation and inflammation during ischemia-reperfusion injury in preexisting diabetes amplifies the proteolytic activity of matrix metalloproteinases (MMPs), thereby contributing to greater vascular injury [i.e., edema and hemorrhagic transformation (HT)] and neurological deficit. FeTTPs, 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (III).
that a treatment had a different effect on an outcome dependent on disease status. A Tukey’s test was used to adjust for the multiple comparisons to assess significant interaction effects from all analyses. For analysis of mortality, a Fisher’s exact test was performed, due to small frequencies, within each treatment to examine whether mortality rates were different in control and diabetic mice. Zelens’ exact test for homogeneity was used to examine whether the mortality rates were homogeneous across treatments. If mortality was homogeneous across rates were different in control and diabetic mice. A Tukey’s test was used to adjust for the multiple comparisons to assess significant interaction effects from all analyses.

**RESULTS**

**Metabolic parameters and mortality in experimental stroke groups**

<table>
<thead>
<tr>
<th></th>
<th>Untreated</th>
<th>FeTPPs (10 mg/kg ip)</th>
<th>Curcumin (250 mg/kg ip)</th>
<th>Minocycline (20 mg/kg ip)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NG D</td>
<td>NG D</td>
<td>NG D</td>
<td>NG D</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>293 ± 4</td>
<td>307.6 ± 3</td>
<td>299.4 ± 7</td>
<td>307.2 ± 5</td>
</tr>
<tr>
<td>Blood glucose, mg/dl</td>
<td>102 ± 4</td>
<td>241 ± 22*</td>
<td>105 ± 5</td>
<td>255 ± 16*</td>
</tr>
<tr>
<td>Mortality, no. of animals/total (%)</td>
<td>3/15 (20)</td>
<td>1/16 (6.3)</td>
<td>3/8 (37.5)</td>
<td>0/6 (0)</td>
</tr>
</tbody>
</table>

Results are given as means ± SE. NG, normoglycemia; D, diabetes; FeTPPs, 5,10,15,20-tetakis(4-sulfonatophenyl)propyryrin iron (III). *P < 0.05 vs. untreated NG.

Evaluation of infarct and edema. Infarcted regions were identified on TTC-stained brain slices to determine the extent of neuronal damage (Fig. 3A). Infarct size, expressed as a percentage of the total ischemic hemisphere, was determined for all experimental groups (Fig. 3B). FeTPPs therapy did not alter the extent of neuronal damage in normoglycemic animals; however, both curcumin and minocycline treatments reduced infarct size by ~20% (P < 0.05 vs. untreated normoglycemic animals). Edema formation, expressed as edema/infarct size, was quantified as the percent difference between ischemic and nonischemic hemispheres, correcting for ischemic lesion volume. Stroke-induced edema formation was similar in all normoglycemic treatment groups, with the exception of animals receiving minocycline at reperfusion (Fig. 3C); brain edema in untreated diabetic animals compared with their normoglycemic counterparts (P < 0.05; Fig. 2C). Administration of FeTPPs at reperfusion reduced microscopic bleeding to undetectable levels. Curcumin and minocycline therapies were also effective in reducing microscopic bleeding in diabetic animals (P < 0.05 vs. untreated diabetic animals). Analysis of the bleeding data using 2 × 2 ANOVA indicated that a disease and drug interaction such that both acute treatment with FeTPPs and minocycline reduced microscopic bleeding in diabetic animals but not in the corresponding normoglycemic animals (P = 0.0003 and P = 0.0011, respectively; Fig. 2C). Curcumin, on the other hand, augmented microscopic bleeding in the ischemic brain hemispheres of control animals but reduced bleeding in diabetic animals (P = 0.0016).

**Evaluation of HT.** Arterial blood gases in control and diabetic groups after the induction of anesthesia before MCAO surgery are shown in Table 1. Weight-matched (270–320 g) diabetic animals displayed moderate levels of hyperglycemia compared with normoglycemic control animals. Furthermore, there were no differences in poststroke mortality rates between groups.

**RESULTS**

Table 1. *Metabolic parameters and mortality in experimental stroke groups*

<table>
<thead>
<tr>
<th></th>
<th>Untreated</th>
<th>FeTPPs (10 mg/kg ip)</th>
<th>Curcumin (250 mg/kg ip)</th>
<th>Minocycline (20 mg/kg ip)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NG D</td>
<td>NG D</td>
<td>NG D</td>
<td>NG D</td>
</tr>
<tr>
<td>Percent decrease Postocclusion</td>
<td>45 ± 2</td>
<td>47 ± 2</td>
<td>43 ± 2</td>
<td>53 ± 7</td>
</tr>
<tr>
<td>Percent increase Postreperfusion</td>
<td>29 ± 2</td>
<td>13 ± 5*</td>
<td>27 ± 3</td>
<td>9 ± 13*</td>
</tr>
</tbody>
</table>

Results are given as means ± SE. *P < 0.01 vs. NG.
that group was slightly higher ($P < 0.05$ vs. untreated normoglycemic animals). As we have previously shown, infarcted tissue volume was ~40% smaller in brains extracted from diabetic animals compared with untreated normoglycemic animals ($P < 0.001$; Fig. 3A). Furthermore, the infarcted zones were typically confined to the striatum in diabetic animals (Fig. 3A), whereas ischemic lesions in normoglycemic animals were found in both striatal and cortical brain regions (Fig. 3A). Infarct size in diabetic animals did not change with acute FeTPPs, curcumin, or minocycline therapy. Edema was greater in brains from untreated diabetic animals compared with their untreated normoglycemic counterparts ($P < 0.001$). Edema formation was not reduced by acute FeTPPs treatment; however, curcumin and minocycline therapies mitigated brain edema in diabetic animals. A disease-treatment interaction was detected with curcumin such that it reduced edema in diabetic animals but not in normoglycemic animals ($P = 0.0013$). Similarly, acute minocycline treatment reduced edema in diabetic animals but not in normoglycemic animals ($P = 0.0001$).

**Neurological assessment.** A beam walk test was used to observe vestibulomotor function after stroke in control and diabetic animals (Fig. 4A). Postoperative beam walk performance was poor in untreated normoglycemic animals; these animals could not traverse the beam, but they could stay balanced. Acute treatment with FeTPPs or minocycline did not improve beam walk performance in untreated normoglycemic animals. Curcumin therapy significantly improved poststroke beam walk scores ($P < 0.01$ vs. untreated animals). A modified Bederson test was used to determine the impact of stroke on global neurological function (Fig. 4B). Abnormal postural responses were observed in all untreated normoglycemic animals after stroke. Administration of FeTPPs, curcumin, or minocycline at reperfusion did not improve modified Bederson scores in normoglycemic animals. Poststroke forelimb strength

---

**Fig. 2. Detection of macroscopic and microscopic bleeding as an indicator of vascular integrity in normoglycemic and diabetic animals after stroke.**

A: representative images of unstained brain slices (slice D was selected for each experimental group). B: small amounts of macroscopic bleeding were detected in untreated brain slices from normoglycemic animals. Results from the visual inspection of macroscopic bleeding in untreated brain slices indicated that poststroke bleeding was more severe in untreated diabetic animals compared with untreated normoglycemic animals, and all treatments showed a trend for reduced macroscopic bleeding. C: quantitative analysis of HT was reported as hemoglobin concentration in the ischemic hemispheres of experimental stroke groups. Results from the colorimetric hemoglobin detection assay were normalized by the absorbance of the drug in the brains of nonstressed animals for each group. Low levels of microscopic bleeding were measured in the ischemic hemispheres of normoglycemic animals. These levels remained unchanged by FeTPPs and minocycline therapies but were worsened in animals receiving curcumin treatment at reperfusion. HT, as measured by hemoglobin concentration, was greater in untreated diabetic animals. Acute treatment with FeTPPs, curcumin, and minocycline at reperfusion reduced bleeding in diabetic animals after ischemic stroke. Results are given as means ± SE; n = 4–13. All values in this data set were below minimum detection levels; *$P < 0.05$ vs. untreated normoglycemic animals; **$P < 0.05$ vs. untreated diabetic animals; †$P = 0.071$ vs. untreated diabetic animals; *$P = 0.0003$, ‡$P = 0.0016$, and †$P = 0.0011$, disease by treatment interaction compared with untreated normoglycemic and diabetic animals.
Fig. 3. Evaluation of infarct volume and edema in normoglycemic and diabetic experimental stroke groups. A: representative digital images of necrotic tissue (white) in 2,3,5-triphenyltetrazolium chloride-stained coronal brain slices (slice D was selected for each group). B: quantification of infarct size. Untreated normoglycemic animals developed infarcts that occupied ~60% of the total ischemic hemisphere. Single-dose administration of either curcumin or minocycline reduced infarct volume in normoglycemic animals; FeTPPs treatment had no effect. Diabetic animals consistently developed smaller infarcts than normoglycemic animals. Single-dose administration of FeTPPs, curcumin, or minocycline at reperfusion did not alter the magnitude of infarcted brain tissue in diabetic animals. C: ischemic stroke induced brain edema in normoglycemic animals. Acute treatment with FeTPPs or curcumin had no effect on edema formation in normoglycemic animals; however, there was a slight increase in brain edema with minocycline therapy. Edema was greater in untreated diabetic animals compared with untreated normoglycemic animals. Edema formation in animals with preexisting diabetes was not reduced by FeTPPs or curcumin when administered in a single dose at reperfusion. Acute minocycline treatment effectively reduced brain edema in diabetic animals. Results are given as means ± SE; n = 5–13. *P < 0.05 vs. untreated normoglycemic or diabetic animals; **P < 0.001 vs. untreated normoglycemic animals; ***P = 0.0033, ^P = 0.016, *P = 0.0013, and ^P = 0.0001, disease by treatment interaction compared with untreated control and diabetic animals.

was evaluated in all experimental groups (Fig. 4C). Untreated normoglycemic animals displayed grip strength deficits after stroke. Acute treatment with FeTPPs or curcumin did not improve postoperative performance. However, minocycline therapy effectively reduced poststroke grip strength deficits in normoglycemic animals. Poststroke beam walk performance in untreated diabetic animals was similar to their untreated normoglycemic counterparts (Fig. 4A). Single-dose administration of FeTPPs and curcumin but not minocycline improved poststroke beam walk performance in diabetic animals (P < 0.05 and P < 0.01 vs. untreated animals). Global neurological function was significantly worse in untreated diabetic animals compared with untreated normoglycemic animals (P < 0.05; Fig. 4B). Acute FeTPPs or minocycline therapies did not improve modified Bederson scores in diabetic animals. Only curcumin treatment effectively improved poststroke Bederson test performance in diabetic animals (P < 0.05). Furthermore, a disease-treatment interaction was detected in which curcumin therapy improved poststroke Bederson test performance in diabetic but not normoglycemic animals (P = 0.0016). Stroke-induced grip strength deficit in untreated diabetic animals was greater than in normoglycemic animals (Fig. 4C). FeTPPs treatment did not correct lost grip strength in diabetic animals; however, curcumin and minocycline improved grip strength deficit in diabetic animals (P < 0.05 vs. untreated...
normoglycemic animals). These analyses also pointed to differences in response to treatment in control versus diabetic animals. There was a disease-treatment interaction for FeTPPS ($P = 0.034$) such that the deficit was greater in control animals compared with diabetic animals after treatment (Fig. 4C). Curcumin treatment had no effect in normoglycemic animals but improved the deficit in diabetic animals ($P = 0.049$).

Measurement of Cerebrovascular MMP Activity

MMP-9 gelatinolytic activity measured in the macrovessels from ischemic brain hemispheres was similar between untreated normoglycemic and diabetic animals. All treatments reduced MMP-9 activity (Fig. 5). There were no changes in MMP-2 activity (not shown).
DISCUSSION

Diabetic patients and experimental animal models sustain greater neurovascular injury and functional deficits in AIS. Disruption of cerebrovascular integrity is associated with increased MMP-9 activity and expression. Therefore, the objective of the present study was to determine whether the acute inhibition of MMP-9 at reperfusion by minocycline or through inhibition of its upstream activators peroxynitrite and NF-κB would improve HT and functional outcomes in diabetic stroke. Major findings from this study indicate that 24 h poststroke, bleeding was improved by a single-dose administration of FeTPPs, curcumin, or minocycline at reperfusion in diabetic animals and that this was associated with reduced MMP-9 activity. Varying degrees of improvement in neurological deficits were observed in diabetic animals receiving these acute therapies. Infarct size, however, was not altered by direct peroxynitrite scavenging, suppression of inflammation, or inhibition of MMPs. The multiple disease and drug interactions noted in this study strongly suggest that these treatments have differential effects on control and diabetic animals, and, as such, therapeutic targets for neurovascular protection may differ in disease states.

Of the three therapies, single-dose administration of curcumin at reperfusion offered the most benefit by reducing edema, bleeding, and neurological deficit after focal cerebral ischemia in diabetes. A nonspecific NF-κB inhibitor, curcumin has emerged as a promising candidate in the treatment of neurodegenerative diseases because of its antioxidant, anti-inflammatory, and antiapoptotic properties (29, 61). A recent report by King et al. (37) investigated the potential role for curcumin in mitigating neurovascular injury in a model of intracerebral hemorrhage. The researchers demonstrated that curcumin administration (150 mg/kg ip) decreased hematoma size, BBB permeability, and edema postinjury. Evidence in experimental stroke models suggests that a single dose within 30 min to 1 h of focal cerebral ischemia protects against peroxynitrite-mediated BBB disruption (32, 57). Delayed treatment within 4 h of ischemia has also been observed to reduce infarct size and improve neurological outcomes after stroke (14). In the present study, we did not anticipate further reductions in infarct volume in diabetic animals because the lesion size was already very small in untreated animals. However, consistent with earlier studies in normoglycemic animals, curcumin was effective in reducing infarct size in the control group. Given its ability to resolve hematoma within 72 h postinjury in the intracerebral hemorrhage model, we expected only modest improvements in bleeding with a single dose of curcumin at reperfusion. Visual inspection of macroscopic bleeding, however, indicated that curcumin treatment at reperfusion reduced bleeding in both control and diabetic animals. Interestingly, microscopic bleeding was reduced by half in the diabetic group that received curcumin treatment. Even more surprising was the curcumin-mediated increase in microscopic bleeding in the control group despite a reduction in MMP-9 activity. While we do not have an explanation for this finding, it is possible that curcumin is also inhibiting potential vaso-protective mechanisms in otherwise health animals.

NF-κB activation prompts the release of proinflammatory cytokines that promote increases in BBB permeability, thereby allowing neurotoxic blood elements to leak into the infarcted area and exacerbate ischemic injury (43). Improvement of neurological deficits in diabetic animals may be an indirect effect of reducing edema and hemorrhage in these animals. Conversely, failure to attenuate bleeding in control animals may have contributed to worse functional outcomes in this treatment group.

We chose to use minocycline for MMP inhibition in the present study because a phase 2 clinical trial (21) recently showed that minocycline reduces plasma MMP-9 activity in acute ischemic stroke patients, which will be further tested in a phase 3 trial. In the present study, acute minocycline treatment also limited vascular damage after acute stroke but only modestly improved poststroke deficits in diabetic animals. Minocycline is a tetracycline derivative that possesses neuroprotective properties that are distinct from its antimicrobial effects (9, 23, 54). Another study (59) reported that neuropro-
reperfusion is not sufficient to reduce neurological impair-
mals, suggesting that single-dose administration of FeTPPs at
ined at treated control animals. Improvements in neurological def-
perischemia would contribute to
hypoxia-induced loss of myogenic tone was not restored
function deficits in diabetes. Thiyagarajan et al. (57) demon-
noctane had no effect on micro-
macroscopic bleeding in control animals was un-
unrelated to the drug’s ability to act as a direct and specific
scavenger of peroxynitrite. Thus, in the present study, we
minocycline treatment would confer neuroprotection by
infarct volume in treated control not diabetic rats. We
also assumed that acute minocycline treatment would attenuate
vascular injury in diabetic animals. Consistent with our hy-
thesis, single-dose administration of minocycline at reperfu-
sion (20 mg/kg ip) was effective in reducing both macro-
protein expression in cerebral microvessels, MMP-3 activity,
thrombolytic model of MCAO using MMP-3- and MMP-9-
deficient mice, Suzuki et al. (56) demonstrated that tissue
plasminogen activator-induced hemorrhage (56).
attenuated in MMP-3
deficient mice, Suzuki et al. (56) demonstrated that tissue
plasminogen activator-induced intracerebral hemorrhage was
attenuated in MMP-3
but not MMP-9
mice, suggesting
that MMP-3 and not MMP-9 is more important in tissue
plasminogen activator-induced hemorrhage (56).
Direct peroxynitrite scavenging by FeTPPs reduced stroke-
duced macro- and microscopic bleeding and vestibulomotor
function deficits in diabetes. Thiyagarajan et al. (57) demon-
strated that delayed administration of FeTPPs at 2 and 6 h
reduced infarct size, edema, and neurological deficits. The
investigators concluded that these effects were mediated by
reductions of peroxynitrite and inhibition of apoptosis (52, 57).
In the present study, we anticipated decreased infarct volume
in FeTPPs-treated control animals. We also predicted that
direct peroxynitrite scavenging with FeTPPs would reduce
bleeding and edema in diabetic animals by preventing per-
oxynitrite-mediated loss of myogenic tone, thus confirming
data reported in a previous ex vivo study from our group (35).
Since hypoxia-induced loss of myogenic tone was not restored
by FeTPPs in MCAs isolated from control animals, we hy-
thesized that this vascular dysfunction would contribute to
hyperperfusion and more bleeding. On the contrary, FeTPPs
did not have an effect on either macro- or microscopic bleeding
in treated control animals. Improvements in neurological def-
citcs were limited to vestibulomotor function in diabetic ani-
mals, suggesting that single-dose administration of FeTPPs at
reperfusion is not sufficient to reduce neurological impair-
ments.
with preexisting diabetes, thus culminating in different stroke outcomes. In conclusion, we have shown that targets of vascular protection in AIS are different in T2D and that future studies are needed to understand why acute treatments at reperfusion conferred greater benefit in our diabetic model of stroke compared with treated control animals. In this way, we will reduce the gap in knowledge of how preexisting diabetes contributes to stroke pathophysiology and will potentially aid in the development of novel therapeutic strategies tailored to the diabetic population.

GRANTS

The work was supported by in part by National Institute of Neurological Disorders and Stroke (NINDS) Grant F31-NS-066746 (to A. I. Kelly-Cobbs). A. Ergul is a research pharmacologist at the Charlie Norwood Veterans Affairs (VA) Medical Center (Augusta, GA). Additional support was provided in part by VA Merit Award BX000347, NINDS Grant NS-054688, and American Heart Association Established Investigator Award 074002N (to A. Ergul). Funding for this work was also provided, in part, by VA Merit Award BX000891 and NINDS Grant NS-063965 (to S. C. Fagan).

DISCLAIMER

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES


